Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eleven Biotherapeutics (EBIO) PT Raised to $8 at Leerink Partners
August 13, 2015 2:13 PM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on Eleven Biotherapeutics (NASDAQ: EBIO) from $6 up to $8.35 following Q2 results and upside to EBI-005 phase 3 readout.
Gerberry noted that EBIO's Q2 loss of about $7 million was slightly narrower than the firm's outlook for a loss of about $8 million, which... More
Market Wrap: Markets Fend-off Further Yuan Slump; ITG Enters 'Dark Pool' Settlement; Cisco Ramps on Results; Pearson OKs Economist Group Sale
August 12, 2015 5:26 PM EDTMarket wrap for August 12th
End of the Day: S&P 500 up 2.0 to 2,086.05; Dow Jones down 0.3 to 17,402.51; Nasdaq up 7.6 to 5,044.39
Market Brief: Stocks moved into positive territory late Wednesday as they looked to stave off broader pressure tied to China devaluing the yuan.
Macy's slumped amid mixed data points; the retailer's Q2 results laggest expectations, while it also announced expansion deals, which included a flagship store on Alibaba's Tmall.
Alibaba itself was hit after missing consensus Q2 estimates.
Ceres and... More
